Loxo Oncology Inc (NASDAQ:LOXO) price target set to $200.00 by Piper Jaffray Companies

ME Staff
-
0

Analyst Ratings For Loxo Oncology Inc (NASDAQ:LOXO)

Today, Piper Jaffray Companies set its price target on Loxo Oncology Inc (NASDAQ:LOXO) to $200.00 per share.

There are 13 Buy Ratings, 2 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Loxo Oncology Inc (NASDAQ:LOXO) is Buy with a consensus target price of $190.4167 per share, a potential 29.54% upside.

Some recent analyst ratings include

  • 11/14/2018-Loxo Oncology Inc (NASDAQ:LOXO) has coverage initiated with a Strong-Buy ➝ Strong-Buy rating and $235.00 price target
  • 10/22/2018-Loxo Oncology Inc (NASDAQ:LOXO) had its Buy rating reiterated by William Blair
  • 10/22/2018-Loxo Oncology Inc (NASDAQ:LOXO) had its Buy rating reiterated by Cowen


  • On 10/4/2018 Jennifer Burstein, VP, sold 2,500 with an average share price of $164.92 per share and the total transaction amounting to $412,300.00.
  • On 10/4/2018 Joshua H Bilenker, CEO, sold 20,000 with an average share price of $164.94 per share and the total transaction amounting to $3,298,800.00.
  • On 10/4/2018 Naarden Jacob Van, Insider, sold 10,000 with an average share price of $165.13 per share and the total transaction amounting to $1,651,300.00.
  • On 10/1/2018 Lori Anne Kunkel, Director, sold 5,000 with an average share price of $170.37 per share and the total transaction amounting to $851,850.00.
  • On 9/13/2018 Jennifer Burstein, VP, sold 2,500 with an average share price of $166.96 per share and the total transaction amounting to $417,400.00.
  • On 9/13/2018 Joshua H Bilenker, CEO, sold 20,000 with an average share price of $166.20 per share and the total transaction amounting to $3,324,000.00.
  • On 9/13/2018 Naarden Jacob Van, Insider, sold 10,000 with an average share price of $166.32 per share and the total transaction amounting to $1,663,200.00.

About Loxo Oncology Inc (NASDAQ:LOXO)
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Recent Trading Activity for Loxo Oncology Inc (NASDAQ:LOXO)
Shares of Loxo Oncology Inc closed the previous trading session at 144,54 −8,16 5,34 % with 144.53 shares trading hands.